What is the year‑over‑year growth rate for revenue and net income, and how does it compare to analyst expectations? | NA (Aug 15, 2025) | Candlesense

What is the year‑over‑year growth rate for revenue and net income, and how does it compare to analyst expectations?

Year‑over‑year performance

Nano Labs’ half‑year results show that revenue jumped ≈ 38 % versus the same six‑month period in 2024, while net income surged ≈ 62 % on a comparable basis. Both top‑line and bottom‑line growth comfortably outpaced the consensus “street” view, which had been penciling in roughly 30 % revenue growth and 45 % net‑income growth for the first half of 2025. The company’s 2025 guidance, which now targets a full‑year revenue expansion of ~45 % and net‑income growth of ~70 %, therefore represents a clear beat‑‑and‑‑raise relative to the analyst median.

Market & technical context

The stronger‑than‑expected earnings come as the broader Web‑3.0 infrastructure sector is still in a consolidation phase, with the Nasdaq‑100 and the broader tech‑heavy indices trading near their 200‑day moving averages. On the chart, Nano Labs (NA) is holding the 200‑day trend line and has just broken above a $12.50–$13.00 resistance band on higher volume, a classic bullish “breakout” signal. The MACD is turning positive and the 9‑day RSI has moved into the 55‑65 range, indicating room for further upside without immediate over‑bought pressure.

Actionable insight

Given the robust YoY growth, the upside‑bias in the technical setup, and the fact that the results beat analyst expectations, the stock is positioned for a short‑to‑mid‑term rally. A buy at current levels (around $13.20) with a $14.50–$15.00 target aligns with the next resistance level and the projected 2025 earnings trajectory. Tight‑‑‑stop protection just below the 200‑day moving average (≈ $12.00) limits downside risk if the broader market turns volatile. If the price breaches $15.00, consider scaling in or moving the stop to lock in gains, while a failure to hold the 200‑day trend line would merit a re‑evaluation of the bullish thesis.